Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307830

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307830

NA Fat Reduction Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 659 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

North America fat reduction market is expected to reach USD 11,773.56 million by 2033 from USD 4,201.57 million in 2022, growing at a CAGR of 9.9% during the forecast period of 2023 to 2033.

Market Segmentation:

North America Fat Reduction Market, By Type (Surgical Fat Reduction, Non-Invasive Fat Reduction, and Minimally Invasive), Application (Abdominal Fat, Thighs Fat, Buttock Fat, Upper-Arm Fat, Facial Fat, and Knee Fat), Gender (Female, Male), Age Group (Adult, Geriatric, and Child), End-User (Hospitals, Multi-Specialty Clinics, Dermatology Centers, Medical Spas, and Beauty Centers), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (U.S., Canada, Mexico, Costa Rica, Dominican Republic, Panama, El Salvador, Guatemala, Honduras, Nicaragua) - Industry Trends and Forecast to 2033.

Overview of North America Fat Reduction Market Dynamics:

  • Driver
  • Increasing demand for minimally invasive and non-invasive procedures
  • Restrain
  • High cost of procedures
  • Opportunity
  • Customized treatment plans and integration with other aesthetic procedures

Market Players:

The key market players operating in the North America fat reduction market are listed below:

  • AbbVie Inc.
  • Cynosure
  • Candela Corporation
  • Alma Lasers
  • Solta Medical (Subsidiary of Bausch & Lomb Incorporated)
  • Merz Pharma
  • Cutera
  • MicroAire Surgical Instruments, LLC.
  • Others
Show more

TABLE OF CONTENTS

1 INTRODUCTION 208

  • 1.1 OBJECTIVES OF THE STUDY 208
  • 1.2 MARKET DEFINITION 208
  • 1.3 OVERVIEW OF THE NORTH AMERICA FAT REDUCTION MARKET 208
  • 1.4 CURRENCY AND PRICING 210
  • 1.5 LIMITATIONS 210
  • 1.6 MARKETS COVERED 211

2 MARKET SEGMENTATION 216

  • 2.1 MARKETS COVERED 216
  • 2.2 GEOGRAPHICAL SCOPE 217
  • 2.3 YEARS CONSIDERED FOR THE STUDY 218
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 219
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 222
  • 2.6 MULTIVARIATE MODELLING 223
  • 2.7 TYPE LIFELINE CURVE 223
  • 2.8 DBMR MARKET POSITION GRID 224
  • 2.9 VENDOR SHARE ANALYSIS 225
  • 2.10 MARKET APPLICATION COVERAGE GRID 226
  • 2.11 SECONDARY SOURCES 227
  • 2.12 ASSUMPTIONS 227

3 EXECUTIVE SUMMARY 228

4 PREMIUM INSIGHT 232

  • 4.1 PESTEL ANALYSIS 234
  • 4.2 PORTER'S FIVE FORCES 235
  • 4.3 MARKET ANALYSIS 236
  • 4.4 NORTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 237
    • 4.4.1 U.S. 237
    • 4.4.2 CANADA 238
    • 4.4.3 MEXICO 239
    • 4.4.4 COSTA RICA 240
    • 4.4.5 DOMINICIAN REPUBLIC 241
    • 4.4.6 PANAMA 242
    • 4.4.7 EL SALVADOR 243
    • 4.4.8 GAUTEMALA 244
    • 4.4.9 HONDURAS 245
    • 4.4.10 NICARAGUA 246
  • 4.5 BRAND ANALYSIS 247
    • 4.5.1 KYBELLA 247
    • 4.5.2 AQUALYX 248
  • 4.6 PRICING ANALYSIS (USD) 249
    • 4.6.1 NORTH AMERICA 249
      • 4.6.1.1 U.S. 249
      • 4.6.1.2 CANADA 249
      • 4.6.1.3 MEXICO 249
      • 4.6.1.4 COSTA RICA 250
      • 4.6.1.5 DOMINICIAN REPUBLIC 250
      • 4.6.1.6 PANAMA 250
      • 4.6.1.7 EL SALVADOR 251
      • 4.6.1.8 GAUTEMALA 251
      • 4.6.1.9 HONDURAS 251
      • 4.6.1.10 NICARAGUA 252
  • 4.7 PATENT ANALYSIS OF THE NORTH AMERICA FAT REDUCTION MARKET 253
    • 4.7.1 U.S. 253
      • 4.7.1.1 METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID 253
      • 4.7.1.2 COMPOSITIONS COMPRISING DEOXYCHOLIC ACID AND SALTS THEREOF SUITABLE FOR USE IN TREATING EAT DEPOSITS 254
      • 4.7.1.3 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 255
      • 4.7.1.4 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 255
    • 4.7.2 CANADA 256
      • 4.7.2.1 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 256
      • 4.7.2.2 BELKYRA 256
      • 4.7.2.3 BELKYRA 257
      • 4.7.2.4 BELKYRA 257
    • 4.7.3 MEXICO 258
      • 4.7.3.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF. 258
      • 4.7.3.2 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF. 258
  • 4.8 PRICING ANALYSIS (USD) 259
    • 4.8.1 KYBELLA 259
    • 4.8.2 COOLSCULPTING 261
    • 4.8.3 COOLSCULPTING ELITE 263
    • 4.8.4 COOLTONE 265

5 INDUSTRY INSIGHTS: 268

  • 5.1 DEMOGRAPHIC TRENDS: 269
  • 5.2 CONCLUSION: 270

6 NORTH AMERICA FAT REDUCTION MARKET, REGULATIONS 271

  • 6.1 U.S. 271
    • 6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 271
    • 6.1.2 POST-MARKETING SURVEILLANCE: 273
    • 6.1.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 273
  • 6.2 CANADA 274
    • 6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 274
    • 6.2.2 LICENSING AND REGISTRATION 275
    • 6.2.3 POST EXPIRY OF PATENT REGIME 275
    • 6.2.4 POST-MARKETING SURVEILLANCE 275
  • 6.3 MEXICO 276
    • 6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 276
    • 6.3.2 REGULATORY APPROVAL AGENCIES 276
    • 6.3.3 LICENSING AND REGISTRATION 277
    • 6.3.4 POST-MARKETING SURVEILLANCE 277
  • 6.4 DOMINICAN REPUBLIC 277
    • 6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 277
    • 6.4.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 278
    • 6.4.3 TIMELINE 279
  • 6.5 GUATEMALA 279
    • 6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 279
    • 6.5.2 REGULATORY APPROVAL AGENCIES 279
    • 6.5.3 LICENSING AND REGISTRATION 280
    • 6.5.4 POST-MARKETING SURVEILLANCE 280
    • 6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 280
  • 6.6 HONDURAS 280
    • 6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 280
    • 6.6.2 REGULATORY APPROVAL AGENCIES 280
  • 6.7 NICARAGUA 281
    • 6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 281
    • 6.7.2 LICENSING AND REGISTRATION 281
    • 6.7.3 POST-MARKETING SURVEILLANCE 281

7 PIPELINE ANALYSIS OF THE NORTH AMERICA FAT REDUCTION MARKET 282

8 MARKET ACCESS 289

  • 8.1 MANUFACTURER AND STRATEGIC DEALS 289
  • 8.2 CURRENT TREATMENT PRACTICES 289
  • 8.3 IMPACT OF UPCOMING THERAPY 290

9 MARKET OVERVIEW 291

  • 9.1 DRIVERS 293
    • 9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 293
    • 9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 294
    • 9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 295
    • 9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 296
  • 9.2 RESTRAINTS 297
    • 9.2.1 HIGH COST OF PROCEDURES 297
    • 9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 298
    • 9.2.3 PRODUCT RECALL 298
  • 9.3 OPPORTUNITIES 299
    • 9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 299
    • 9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 300
    • 9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 302
  • 9.4 CHALLENGES 304
    • 9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 304
    • 9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 304

10 NORTH AMERICA FAT REDUCTION MARKET, BY TYPE 306

  • 10.1 OVERVIEW 307
  • 10.2 SURGICAL FAT REDUCTION 310
    • 10.2.1 LIPOSUCTION 311
      • 10.2.1.1 BY TYPE 312
        • 10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 312
        • 10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 313
        • 10.2.1.1.3 TUMESCENT LIPOSUCTION 313
        • 10.2.1.1.4 SUPER-WET TECHNIQUE 313
      • 10.2.1.2 BY APPLICATION 313
        • 10.2.1.2.1 ABDOMINAL FAT 314
        • 10.2.1.2.2 THIGHS FAT 314
        • 10.2.1.2.3 BUTTOCK FAT 314
        • 10.2.1.2.4 UPPER-ARM FAT 314
        • 10.2.1.2.5 FACIAL FAT-DEPOSITS 314
        • 10.2.1.2.5.1 SUBMENTAL AREAS 315
        • 10.2.1.2.5.2 MALAR 315
        • 10.2.1.2.5.3 MANDIBULAR 315
        • 10.2.1.2.6 KNEE FAT 315
    • 10.2.2 SURGICAL REJUVENATION 315
      • 10.2.2.1 FACE LIFT 316
      • 10.2.2.2 NECK LIFT 316
    • 10.2.3 CHIN IMPLANT 316
      • 10.2.3.1 SILICONE CHIN IMPLANTS 317
      • 10.2.3.2 OTHERS 317
    • 10.2.4 PORUS IMPLANTS 317
      • 10.2.4.1 TEFLON 318
      • 10.2.4.2 GORE-TEX 318
      • 10.2.4.3 MEDPORE IMPLANTS 318
  • 10.3 NON-INVASIVE FAT REDUCTION 318
    • 10.3.1 CRYOLIPOLYSIS 321
      • 10.3.1.1 COOL SCULPTING 321
      • 10.3.1.2 COOL SCULPTING ELITE 321
      • 10.3.1.3 COOL TONE 322
      • 10.3.1.4 OTHERS 322
        • 10.3.1.4.1 ABDOMINAL FAT 322
        • 10.3.1.4.2 THIGHS FAT 322
        • 10.3.1.4.3 BUTTOCK FAT 323
        • 10.3.1.4.4 UPPER-ARM FAT 323
        • 10.3.1.4.5 FACIAL FAT-DEPOSITS 323
        • 10.3.1.4.6 KNEE FAT 323
    • 10.3.2 ULTRASOUND 323
      • 10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 324
      • 10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 324
        • 10.3.2.2.1 ABDOMINAL FAT 325
        • 10.3.2.2.2 THIGHS FAT 325
        • 10.3.2.2.3 BUTTOCK FAT 325
        • 10.3.2.2.4 UPPER-ARM FAT 325
        • 10.3.2.2.5 FACIAL FAT-DEPOSITS 325
        • 10.3.2.2.6 KNEE FAT 325
    • 10.3.3 RADIOFREQUENCY 326
      • 10.3.3.1 ABDOMINAL FAT 326
      • 10.3.3.2 THIGHS FAT 326
      • 10.3.3.3 BUTTOCK FAT 326
      • 10.3.3.4 UPPER-ARM FAT 326
      • 10.3.3.5 FACIAL FAT-DEPOSITS 327
      • 10.3.3.6 KNEE FAT 327
    • 10.3.4 LOW LEVEL LASER THERAPY 327
      • 10.3.4.1 ABDOMINAL FAT 327
      • 10.3.4.2 THIGHS FAT 327
      • 10.3.4.3 BUTTOCK FAT 328
      • 10.3.4.4 UPPER-ARM FAT 328
      • 10.3.4.5 FACIAL FAT-DEPOSITS 328
      • 10.3.4.6 KNEE FAT 328
    • 10.3.5 OTHERS 328
  • 10.4 MINIMALLY INVASIVE 328
    • 10.4.1 INJECTION LIPOLYSIS 330
      • 10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 330
        • 10.4.1.1.1 KYBELLA/BELKYRA 331
        • 10.4.1.1.1.1 FACIAL FAT-DEPOSITS 332
        • 10.4.1.1.1.2 UPPER-ARM FAT 332
        • 10.4.1.1.1.3 ABDOMINAL FAT 332
        • 10.4.1.1.1.4 THIGHS FAT 332
        • 10.4.1.1.1.5 KNEE FAT 332
        • 10.4.1.1.1.6 BUTTOCK FAT 332
        • 10.4.1.1.2 AQUALYX 333
        • 10.4.1.1.2.1 FACIAL FAT-DEPOSITS 333
        • 10.4.1.1.2.2 UPPER-ARM FAT 333
        • 10.4.1.1.2.3 ABDOMINAL FAT 333
        • 10.4.1.1.2.4 THIGHS FAT 334
        • 10.4.1.1.2.5 KNEE FAT 334
        • 10.4.1.1.2.6 BUTTOCK FAT 334
      • 10.4.1.2 PHOSPHATIDYLCHOLINE 334
        • 10.4.1.2.1 FACIAL FAT-DEPOSITS 335
        • 10.4.1.2.2 UPPER-ARM FAT 335
        • 10.4.1.2.3 ABDOMINAL FAT 335
        • 10.4.1.2.4 THIGHS FAT 335
        • 10.4.1.2.5 KNEE FAT 335
        • 10.4.1.2.6 BUTTOCK FAT 335
      • 10.4.1.3 OTHERS 335
    • 10.4.2 OTHERS 335

11 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION 336

  • 11.1 OVERVIEW 337
  • 11.2 ABDOMINAL FAT 340
  • 11.3 THIGHS FAT 341
  • 11.4 BUTTOCK FAT 342
  • 11.5 UPPER-ARM FAT 343
  • 11.6 FACIAL FAT-DEPOSITS 344
    • 11.6.1 SUBMENTAL AREAS 345
    • 11.6.2 MANDIBULAR 345
    • 11.6.3 MALAR 345
  • 11.7 KNEE FAT 345

12 NORTH AMERICA FAT REDUCTION MARKET, BY GENDER 347

  • 12.1 OVERVIEW 348
  • 12.2 FEMALE 351
  • 12.3 MALE 352

13 NORTH AMERICA FAT REDUCTION MARKET, BY AGE GROUP 353

  • 13.1 OVERVIEW 354
  • 13.2 ADULT 357
  • 13.3 GERIATRIC 358
  • 13.4 CHILD 359

14 NORTH AMERICA FAT REDUCTION MARKET, BY END USER 361

  • 14.1 OVERVIEW 362
  • 14.2 HOSPITALS 365
    • 14.2.1 BY TYPE 366
      • 14.2.1.1 PRIVATE 366
      • 14.2.1.2 PUBLIC 366
    • 14.2.2 BY CATEGORY 366
      • 14.2.2.1 TIER 1 367
      • 14.2.2.2 TIER 2 367
      • 14.2.2.3 TIER 3 367
  • 14.3 MULTISPECIALTY CLINICS 367
  • 14.4 DERMATOLOGY CENTERS 368
  • 14.5 MEDICAL SPAS AND BEAUTY CENTERS 369
  • 14.6 OTHERS 370
Show more

15 NORTH AMERICA FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 372

  • 15.1 OVERVIEW 373
  • 15.2 DIRECT TENDERS 376
  • 15.3 RETAIL SALES 377
  • 15.4 THIRD PARTY DISTRIBUTORS 378
  • 15.5 OTHERS 379

16 NORTH AMERICA FAT REDUCTION MARKET, BY REGION 380

  • 16.1 NORTH AMERICA 381
    • 16.1.1 U.S. 401
    • 16.1.2 CANADA 419
    • 16.1.3 MEXICO 436
    • 16.1.4 COSTA RICA 454
    • 16.1.5 DOMINICAN REPUBLIC 472
    • 16.1.6 PANAMA 490
    • 16.1.7 EL SALVADOR 508
    • 16.1.8 GUATEMALA 525
    • 16.1.9 HONDURAS 543
    • 16.1.10 NICARAGUA 560

17 NORTH AMERICA FAT REDUCTION MARKET, COMPANY LANDSCAPE 577

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 577

18 NORTH AMERICA FAT REDUCTION MARKET, COMPANY LANDSCAPE COUNTRY WISE 578

  • 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 578
    • 18.1.1 COMPANY SHARE ANALYSIS: U.S. 578
      • 18.1.1.1 ABBVIE INC. 579
      • 18.1.1.2 CYNOSURE 580
      • 18.1.1.3 ALMA LASERS 581
      • 18.1.1.4 CANDELA CORPORATION 582
      • 18.1.1.5 MERZ PHARMA 583
    • 18.1.2 COMPANY SHARE ANALYSIS: CANADA 584
      • 18.1.2.1 COMPANY SHARE ANALYSIS: CANADA 584
      • 18.1.2.2 ABBVIE INC. 585
      • 18.1.2.3 CYNOSURE 586
      • 18.1.2.4 CANDELA CORPORATION 587
      • 18.1.2.5 ALMA LASERS 588
      • 18.1.2.6 MERZ PHARMA 589
    • 18.1.3 COMPANY SHARE ANALYSIS: MEXICO 590
      • 18.1.3.1 COMPANY SHARE ANALYSIS: MEXICO 590
      • 18.1.3.2 ABBVIE INC. 591
      • 18.1.3.3 ALMA LASERS 592
      • 18.1.3.4 CANDELA CORPORATION 593
      • 18.1.3.5 MERZ PHARMA 594
    • 18.1.4 COMPANY SHARE ANALYSIS: COSTA RICA 595
      • 18.1.4.1 COMPANY SHARE ANALYSIS: COSTA RICA 595
      • 18.1.4.2 ALMA LASERS 596
      • 18.1.4.3 CANDELA CORPORATION 597
      • 18.1.4.4 DEXLEVO AESTHETICS 598
    • 18.1.5 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC 599
      • 18.1.5.1 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC 599
      • 18.1.5.2 ABBVIE INC. 600
      • 18.1.5.3 ALMA LASERS 601
    • 18.1.6 COMPANY SHARE ANALYSIS: GUATEMALA 602
      • 18.1.6.1 COMPANY SHARE ANALYSIS: GUATEMALA 602
      • 18.1.6.2 ALMA LASERS 603
      • 18.1.6.3 CANDELA CORPORATION 604
    • 18.1.7 COMPANY SHARE ANALYSIS: HONDURUS 605
      • 18.1.7.1 COMPANY SHARE ANALYSIS: HONDURUS 605
      • 18.1.7.2 ALMA LASERS 606
      • 18.1.7.3 CANDELA CORPORATION 607
    • 18.1.8 COMPANY SHARE ANALYSIS: PANAMA 608
      • 18.1.8.1 COMPANY SHARE ANALYSIS: PANAMA 608
      • 18.1.8.2 ALMA LASERS 609
      • 18.1.8.3 CANDELA CORPORATION 610
    • 18.1.9 COMPANY SHARE ANALYSIS: EL SALVADOR 611
      • 18.1.9.1 COMPANY SHARE ANALYSIS: EL SALVADOR 611
      • 18.1.9.2 ALMA LASERS 612
    • 18.1.10 COMPANY SHARE ANALYSIS: NICARAGUA 613
      • 18.1.10.1 COMPANY SHARE ANALYSIS: NICARAGUA 613
      • 18.1.10.2 ALMA LASERS 614

19 SWOT ANALYSIS 615

20 NORTH AMERICA FAT REDUCTION MARKET, COMPANY PROFILINGS 616

  • 20.1 ABBVIE INC.(2022) 616
    • 20.1.1 COMPANY SNAPSHOT 616
    • 20.1.2 REVENUE ANALYSIS 616
    • 20.1.3 COMPANY SHARE ANALYSIS 617
    • 20.1.4 PRODUCT PORTFOLIO 617
    • 20.1.5 RECENT DEVELOPMENTS 618
  • 20.2 CYNOSURE 619
    • 20.2.1 COMPANY SNAPSHOT 619
    • 20.2.2 COMPANY SHARE ANALYSIS 619
    • 20.2.3 PRODUCT PORTFOLIO 620
    • 20.2.4 RECENT DEVELOPMENTS 620
  • 20.3 ALMA LASERS 621
    • 20.3.1 COMPANY SNAPSHOT 621
    • 20.3.2 COMPANY SHARE ANALYSIS 621
    • 20.3.3 PRODUCT PORTFOLIO 622
    • 20.3.4 RECENT DEVELOPMENT 622
  • 20.4 CANDELA CORPORATION 623
    • 20.4.1 COMPANY SNAPSHOT 623
    • 20.4.2 COMPANY SHARE ANALYSIS 623
    • 20.4.3 PRODUCT PORTFOLIO 624
    • 20.4.4 RECENT DEVELOPMENT 624
  • 20.5 MERZ NORTH AMERICA, INC. 625
    • 20.5.1 COMPANY SNAPSHOT 625
    • 20.5.2 COMPANY SHARE ANALYSIS 625
    • 20.5.3 PRODUCT PORTFOLIO 626
    • 20.5.4 RECENT DEVELOPMENTS 626
  • 20.6 3D AESTHETICS 627
    • 20.6.1 COMPANY SNAPSHOT 627
    • 20.6.2 PRODUCT PORTFOLIO 627
    • 20.6.3 RECENT DEVELOPMENT 627
  • 20.7 ADVIN HEALTH CARE 628
    • 20.7.1 COMPANY SNAPSHOT 628
    • 20.7.2 PRODUCT PORTFOLIO 628
    • 20.7.3 RECENT DEVELOPMENT 628
  • 20.8 BLACK & BLACK SURGICAL 629
    • 20.8.1 COMPANY SNAPSHOT 629
    • 20.8.2 PRODUCT PORTFOLIO 629
    • 20.8.3 RECENT DEVELOPMENT 629
  • 20.9 BTL GROUP OF COMPANIES 630
    • 20.9.1 COMPANY SNAPSHOT 630
    • 20.9.2 PRODUCT PORTFOLIO 630
    • 20.9.3 RECENT DEVELOPMENTS 630
  • 20.10 BAUSCH HEALTH COMPANIES INC. 631
    • 20.10.1 COMPANY SNAPSHOT 631
    • 20.10.2 REVENUE ANALYSIS 631
    • 20.10.3 PRODUCT PORTFOLIO 632
    • 20.10.4 RECENT DEVELOPMENT 632
  • 20.11 CUTERA (2022) 633
    • 20.11.1 COMPANY SNAPSHOT 633
    • 20.11.2 REVENUE ANALYSIS 633
    • 20.11.3 PRODUCT PORTFOLIO 634
    • 20.11.4 RECENT DEVELOPMENT 634
  • 20.12 DEXLEVOAESTHETIC 635
    • 20.12.1 COMPANY SNAPSHOT 635
    • 20.12.2 PRODUCT PORTFOLIO 635
    • 20.12.3 RECENT DEVELOPMENT 635
  • 20.13 ERCHONIA CORPORATION 636
    • 20.13.1 COMPANY SNAPSHOT 636
    • 20.13.2 PRODUCT PORTFOLIO 636
    • 20.13.3 RECENT DEVELOPMENT 636
  • 20.14 FOTONA 637
    • 20.14.1 COMPANY SNAPSHOT 637
    • 20.14.2 PRODUCT PORTFOLIO 637
    • 20.14.3 RECENT DEVELOPMENT 637
  • 20.15 GENESIS BIOSYSTEMS, INC. 638
    • 20.15.1 COMPANY SNAPSHOT 638
    • 20.15.2 PRODUCT PORTFOLIO 638
    • 20.15.3 RECENT DEVELOPMENT 638
  • 20.16 HIRONIC CO., LTD. 639
    • 20.16.1 COMPANY SNAPSHOT 639
    • 20.16.2 REVENUE ANALYSIS 639
    • 20.16.3 PRODUCT PORTFOLIO 640
    • 20.16.4 RECENT DEVELOPMENT 640
  • 20.17 IMPLANTECH 641
    • 20.17.1 COMPANY SNAPSHOT 641
    • 20.17.2 PRODUCT PORTFOLIO 641
    • 20.17.3 RECENT DEVELOPMENTS 642
  • 20.18 INTROPHARMA 643
    • 20.18.1 COMPANY SNAPSHOT 643
    • 20.18.2 PRODUCT PORTFOLIO 643
    • 20.18.3 RECENT DEVELOPMENT 643
  • 20.19 LEADERMA INC. 644
    • 20.19.1 COMPANY SNAPSHOT 644
    • 20.19.2 PRODUCT PORTFOLIO 644
    • 20.19.3 RECENT DEVELOPMENT 644
  • 20.20 LYNTON LASERS LTD 645
    • 20.20.1 COMPANY SNAPSHOT 645
    • 20.20.2 PRODUCT PORTFOLIO 645
    • 20.20.3 RECENT DEVELOPMENT 645
  • 20.21 MENTOR WORLDWIDE LLC (A PART OF JOHNSON & JOHNSON SERVICES, INC.) 646
    • 20.21.1 COMPANY SNAPSHOT 646
    • 20.21.2 REVENUE ANALYSIS 646
    • 20.21.3 PRODUCT PORTFOLIO 647
    • 20.21.4 RECENT DEVELOPMENT 647
  • 20.22 MICROAIRE SURGICAL INSTRUMENTS, LLC. 648
    • 20.22.1 COMPANY SNAPSHOT 648
    • 20.22.2 PRODUCT PORTFOLIO 648
    • 20.22.3 RECENT DEVELOPMENT 648
  • 20.23 MOLLER MEDICAL 649
    • 20.23.1 COMPANY SNAPSHOT 649
    • 20.23.2 PRODUCT PORTFOLIO 649
    • 20.23.3 RECENT DEVELOPMENT 649
  • 20.24 POLLOGEN (A SUBSIDIARY OF LUMENIS BE LTD.) 650
    • 20.24.1 COMPANY SNAPSHOT 650
    • 20.24.2 PRODUCT PORTFOLIO 650
    • 20.24.3 RECENT DEVELOPMENT 650
  • 20.25 SILIMED 651
    • 20.25.1 COMPANY SNAPSHOT 651
    • 20.25.2 PRODUCT PORTFOLIO 651
    • 20.25.3 RECENT DEVELOPMENTS 651
  • 20.26 SURGIFORM INNOVATIVE SURGICAL PRODUCTS 652
    • 20.26.1 COMPANY SNAPSHOT 652
    • 20.26.2 PRODUCT PORTFOLIO 652
    • 20.26.3 RECENT DEVELOPMENT 652
  • 20.27 VENUS CONCEPT 653
    • 20.27.1 COMPANY SNAPSHOT 653
    • 20.27.2 REVENUE ANALYSIS 653
    • 20.27.3 PRODUCT PORTFOLIO 654
    • 20.27.4 RECENT DEVELOPMENT 654

21 QUESTIONNAIRE 655

22 RELATED REPORTS 659

LIST OF TABLES

  • TABLE 1 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 85
  • TABLE 2 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 86
  • TABLE 3 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 87
  • TABLE 4 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 88
  • TABLE 5 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 89
  • TABLE 6 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 90
  • TABLE 7 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 91
  • TABLE 8 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 92
  • TABLE 9 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 93
  • TABLE 10 NUMBER OF PROCEDURES AND AVERAGE COST OF PROCEDURES 94
  • TABLE 11 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 97
  • TABLE 12 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 97
  • TABLE 13 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 97
  • TABLE 14 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 98
  • TABLE 15 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 98
  • TABLE 16 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 98
  • TABLE 17 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 99
  • TABLE 18 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 99
  • TABLE 19 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 99
  • TABLE 20 AVERAGE SELLING PRICE, SALES, NUMBER OF UNIT SOLD 100
  • TABLE 21 EVALUATION OF SAFETY AND EFFICACY OF RZL-012 IN SUBJECTS SEEKING FAT REDUCTION IN THE FLANKS 130
  • TABLE 22 AN OPEN LABEL STUDY THAT WILL TEST SAFETY AND EFFICACY OF RZL-012 INJECTION INTO THE SUBMENTAL FAT IN 10 CHINESE VS. 10 NON-CHINESE SUBJECTS. 130
  • TABLE 23 EVALUATE THE EFFICACY AND SAFETY OF POLYENE PHOSPHATIDYLCHOLINE INJECTION (AYP-101) FOR THE REDUCTION OF SUBMENTAL FAT (AYP-101) 131
  • TABLE 24 A STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CBL-514 INJECTION FOR REDUCING ABDOMINAL SUBCUTANEOUS FAT 131
  • TABLE 25 DETERMINE THE DOSING INTERVAL AND OPTIMAL DOSE OF AYP-101 FOR THE REDUCTION OF SUBMENTAL FAT IN CHIN AREA 132
  • TABLE 26 SAFETY AND EFFICACY OF DEOXYCHOLIC ACID INJECTION FOR REDUCTION OF UPPER INNER THIGH FAT 132
  • TABLE 27 DEOXYCHOLIC ACID INJECTION FOR THE TREATMENT OF SUPERFICIAL LIPOMAS 132
  • TABLE 28 EVALUATION OF SAFETY AND EFFICACY OF DEOXYCHOLIC ACID INJECTION (ATX-101) IN THE REDUCTION OF SUBMENTAL FAT 133
  • TABLE 29 LIPID AND ADIPOKINE PROFILES FOLLOWING SUBCUTANEOUS INJECTION OF ATX-101 INTO ABDOMINAL FAT TISSUE 133
  • TABLE 30 DEOXYCHOLIC ACID INJECTION SUBMENTAL FAT (SMF) MAGNETIC RESONANCE IMAGING (MRI) AND SUBJECT-REPORTED OUTCOME MEASURES STUDY 134
  • TABLE 31 PATIENT EXPERIENCE STUDY OF DEOXYCHOLIC ACID INJECTION 134
  • TABLE 32 STUDY OF DEOXYCHOLIC ACID INJECTION (ATX-101) VERSUS PLACEBO FOR THE REDUCTION OF LOCALIZED SUBCUTANEOUS FAT IN THE SUBMENTAL AREA 134
  • TABLE 33 LONG-TERM FOLLOW-UP STUDY ON SAFETY AND MAINTENANCE OF EFFICACY OF ATX-101 135
  • TABLE 34 SAFETY STUDY OF DEOXYCHOLIC ACID FOR THE REDUCTION OF LOCALIZED SUBCUTANEOUS FAT IN THE SUBMENTAL AREA IN SUBJECTS 65 TO 75 YEARS OF AGE 135
  • TABLE 35 SAFETY STUDY OF ATX-101 (DEOXYCHOLIC ACID) IN SUBJECTS WITH MILD OR EXTREME FULLNESS OF SUBMENTAL FAT 136
  • TABLE 36 OPEN-LABEL STUDY OF DEOXYCHOLIC ACID FOR THE REDUCTION OF LOCALIZED SUBCUTANEOUS FAT IN THE SUBMENTAL AREA 136
  • TABLE 37 AVERAGE COST OF LIPOSUCTION ACROSS THE U.S. 145
  • TABLE 38 AVERAGE COSTS OF CHIN AUGMENTATION ACROSS THE U.S. 145
  • TABLE 39 COST OF LIPOSUCTION IN SOME EUROPEAN COUNTRIES 146
  • TABLE 40 NORTH AMERICA FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 157
  • TABLE 41 NORTH AMERICA SURGICAL FAT REDUTCION IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 158
  • TABLE 42 NORTH AMERICA SURGICAL FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 159
  • TABLE 43 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 160
  • TABLE 44 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 160
  • TABLE 45 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 161
  • TABLE 46 NORTH AMERICA FACIAL FAT-DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 162
  • TABLE 47 NORTH AMERICA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 163
  • TABLE 48 NORTH AMERICA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 164
  • TABLE 49 NORTH AMERICA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (USD MILLION) 164
  • TABLE 50 NORTH AMERICA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (NUMBER OF PROCEDURES) 165
  • TABLE 51 NORTH AMERICA PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 165
  • TABLE 52 NORTH AMERICA PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 166
  • TABLE 53 NORTH AMERICA NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 167
  • TABLE 54 NORTH AMERICA NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 168
  • TABLE 55 NORTH AMERICA NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 168
  • TABLE 56 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 169
  • TABLE 57 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 169
  • TABLE 58 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 170
  • TABLE 59 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 171
  • TABLE 60 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 172
  • TABLE 61 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 172
  • TABLE 62 NORTH AMERICA RADIOFREQUENCY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 174
  • TABLE 63 NORTH AMERICA LOW-LEVEL LASER THERAPY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 175
  • TABLE 64 NORTH AMERICA MINIMALLY INVASIVE IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 177
  • TABLE 65 NORTH AMERICA MINIMALLY INVASIVE IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 177
  • TABLE 66 NORTH AMERICA INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 178
  • TABLE 67 NORTH AMERICA INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 178
  • TABLE 68 NORTH AMERICA DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (USD MILLION) 179
  • TABLE 69 NORTH AMERICA DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (NUMBER OF PROCEDURES) 179
  • TABLE 70 NORTH AMERICA KYBELLA/BELKYRA IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 179
  • TABLE 71 NORTH AMERICA AQUALYX IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 181
  • TABLE 72 NORTH AMERICA PHOSPHATIDYLCHOLINE IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 182
  • TABLE 73 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 187
  • TABLE 74 NORTH AMERICA ABDOMINAL FAT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 188
  • TABLE 75 NORTH AMERICA THIGHS FAT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 189
  • TABLE 76 NORTH AMERICA BUTTOCK FAT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION)) 190
  • TABLE 77 NORTH AMERICA UPPER-ARM FAT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 191
  • TABLE 78 NORTH AMERICA FACIAL FAT-DEPOSITS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 192
  • TABLE 79 NORTH AMERICA FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 193
  • TABLE 80 NORTH AMERICA KNEE FAT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 194
  • TABLE 81 NORTH AMERICA FAT REDUCTION MARKET, BY GENDER, 2019-2033 (USD MILLION) 198
  • TABLE 82 NORTH AMERICA FEMALE IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 199
  • TABLE 83 NORTH AMERICA MALE IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 200
  • TABLE 84 NORTH AMERICA FAT REDUCTION MARKET, BY AGE GROUP, 2019-2033 (USD MILLION) 204
  • TABLE 85 NORTH AMERICA ADULT IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 206
  • TABLE 86 NORTH AMERICA GERIATRIC IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 207
  • TABLE 87 NORTH AMERICA CHILD IN FAT REDUCTION MARKET, BY REGION, 2021-2033 (USD MILLION) 208
  • TABLE 88 NORTH AMERICA FAT REDUCTION MARKET, BY END USER, 2019-2033 (USD MILLION) 212
  • TABLE 89 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 213
  • TABLE 90 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 214
  • TABLE 91 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY CATEGORY, 2019-2033 (USD MILLION) 214
  • TABLE 92 NORTH AMERICA MULTISPECIALITY CLINICS IN FAT REDUCTION MARKET, 2019-2033 (USD MILLION) 216
  • TABLE 93 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 217
  • TABLE 94 NORTH AMERICA MEDICAL SPAS AND BEAUTY CENTERS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 218
  • TABLE 95 NORTH AMERICA OTHERS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 219
  • TABLE 96 NORTH AMERICA FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2033 (USD MILLION) 223
  • TABLE 97 NORTH AMERICA DIRECT TENDERS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 224
  • TABLE 98 NORTH AMERICA RETAIL SALES IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 225
  • TABLE 99 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 226
  • TABLE 100 NORTH AMERICA OTHERS IN FAT REDUCTION MARKET, BY REGION, 2019-2033 (USD MILLION) 227
  • TABLE 101 NORTH AMERICA FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 233
  • TABLE 102 NORTH AMERICA SURGICAL FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 233
  • TABLE 103 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 234
  • TABLE 104 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 234
  • TABLE 105 NORTH AMERICA LIPOSUCTION IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 235
  • TABLE 106 NORTH AMERICA FACIAL FAT-DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 235
  • TABLE 107 NORTH AMERICA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 236
  • TABLE 108 NORTH AMERICA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 236
  • TABLE 109 NORTH AMERICA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (USD MILLION) 236
  • TABLE 110 NORTH AMERICA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (NUMBER OF PROCEDURES) 236
  • TABLE 111 NORTH AMERICA PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 237
  • TABLE 112 NORTH AMERICA PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 237
  • TABLE 113 NORTH AMERICA NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 237
  • TABLE 114 NORTH AMERICA NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 238
  • TABLE 115 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 238
  • TABLE 116 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 238
  • TABLE 117 NORTH AMERICA CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 239
  • TABLE 118 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 239
  • TABLE 119 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 240
  • TABLE 120 NORTH AMERICA ULTRASOUND IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 240
  • TABLE 121 NORTH AMERICA RADIOFREQUENCY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 241
  • TABLE 122 NORTH AMERICA LOW-LEVEL LASER THERAPY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 241
  • TABLE 123 NORTH AMERICA MINIMALLY INVASIVE IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 242
  • TABLE 124 NORTH AMERICA INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 242
  • TABLE 125 NORTH AMERICA INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 242
  • TABLE 126 NORTH AMERICA DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (USD MILLION) 243
  • TABLE 127 NORTH AMERICA DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (NUMBER OF PROCEDURES) 243
  • TABLE 128 NORTH AMERICA KYBELLA/BELKYRA IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 243
  • TABLE 129 NORTH AMERICA PHOSPHATIDYLCHOLINE IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 244
  • TABLE 130 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 244
  • TABLE 131 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (NUMBER OF PROCEDURES) 245
  • TABLE 132 NORTH AMERICA FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 245
  • TABLE 133 NORTH AMERICA FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (NUMBER OF PROCEDURES) 245
  • TABLE 134 NORTH AMERICA FAT REDUCTION MARKET, BY GENDER, 2019-2033 (USD MILLION) 246
  • TABLE 135 NORTH AMERICA FAT REDUCTION MARKET, BY AGE GROUP, 2019-2033 (USD MILLION) 246
  • TABLE 136 NORTH AMERICA FAT REDUCTION MARKET, BY END USER, 2019-2033 (USD MILLION) 247
  • TABLE 137 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 247
  • TABLE 138 NORTH AMERICA HOSPITALS IN FAT REDUCTION MARKET, BY CATEGORY, 2019-2033 (USD MILLION) 248
  • TABLE 139 NORTH AMERICA FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2033 (USD MILLION) 248
  • TABLE 140 U.S. FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 249
  • TABLE 141 U.S. SURGICAL FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 249
  • TABLE 142 U.S. LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 250
  • TABLE 143 U.S. LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 250
  • TABLE 144 U.S. LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 250
  • TABLE 145 U.S. LIPOSUCTION IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 251
  • TABLE 146 U.S. FACIAL FAT-DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 251
  • TABLE 147 U.S. SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 252
  • TABLE 148 U.S. SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 252
  • TABLE 149 U.S. SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 252
  • TABLE 150 U.S. CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (USD MILLION) 252
  • TABLE 151 U.S. CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (NUMBER OF PROCEDURES) 253
  • TABLE 152 U.S. CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 ASP 253
  • TABLE 153 U.S. PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 253
  • TABLE 154 U.S. PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 253
  • TABLE 155 U.S. PORUS IMPLANTS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 254
  • TABLE 156 U.S. NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 254
  • TABLE 157 U.S. NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 254
  • TABLE 158 U.S. NON-INVASIVE FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 255
  • TABLE 159 U.S. CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 255
  • TABLE 160 U.S. CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 255
  • TABLE 161 U.S. CRYOLYPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 256
  • TABLE 162 U.S. CRYOLIPOLYSIS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 256
  • TABLE 163 U.S.ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 257
  • TABLE 164 U.S. ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 257
  • TABLE 165 U.S. ULTRASOUND IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 257
  • TABLE 166 U.S. ULTRASOUND IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 258
  • TABLE 167 U.S. RADIOFREQUENCY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 258
  • TABLE 168 U.S. LOW-LEVEL LASER THERAPY IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 259
  • TABLE 169 U.S. MINIMALLY INVASIVE IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 259
  • TABLE 170 U.S. INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 259
  • TABLE 171 U.S. INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 260
  • TABLE 172 U.S. INJECTION LIPOLYSIS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 260
  • TABLE 173 U.S. DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (USD MILLION) 260
  • TABLE 174 U.S. DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 (NUMBER OF PROCEDURES) 260
  • TABLE 175 U.S. DEOXYCHOLIC ACID INJECTIONS IN FAT REDUCTION MARKET, BY BRAND, 2019-2033 ASP 260
  • TABLE 176 U.S. KYBELLA/BELKYRA IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 261
  • TABLE 177 U.S. PHOSPHATIDYLCHOLINE IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 261
  • TABLE 178 U.S. FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 262
  • TABLE 179 U.S. FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (NUMBER OF PROCEDURES) 262
  • TABLE 180 U.S. FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 ASP 263
  • TABLE 181 U.S. FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 263
  • TABLE 182 U.S. FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (NUMBER OF PROCEDURES) 263
  • TABLE 183 U.S. FACIAL FAT DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 ASP 264
  • TABLE 184 U.S. FAT REDUCTION MARKET, BY GENDER, 2019-2033 (USD MILLION) 264
  • TABLE 185 U.S. FAT REDUCTION MARKET, BY AGE GROUP, 2019-2033 (USD MILLION) 264
  • TABLE 186 U.S. FAT REDUCTION MARKET, BY END USER, 2019-2033 (USD MILLION) 265
  • TABLE 187 U.S. HOSPITALS IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 265
  • TABLE 188 U.S. HOSPITALS IN FAT REDUCTION MARKET, BY CATEGORY, 2019-2033 (USD MILLION) 266
  • TABLE 189 U.S. FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2033 (USD MILLION) 266
  • TABLE 190 CANADA FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 267
  • TABLE 191 CANADA SURGICAL FAT REDUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 267
  • TABLE 192 CANADA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 268
  • TABLE 193 CANADA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 268
  • TABLE 194 CANADA LIPOSUCTION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 268
  • TABLE 195 CANADA LIPOSUCTION IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 269
  • TABLE 196 CANADA FACIAL FAT-DEPOSITS IN FAT REDUCTION MARKET, BY APPLICATION, 2019-2033 (USD MILLION) 269
  • TABLE 197 CANADA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (USD MILLION) 270
  • TABLE 198 CANADA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 (NUMBER OF PROCEDURES) 270
  • TABLE 199 CANADA SURGICAL REJUVENATION IN FAT REDUCTION MARKET, BY TYPE, 2019-2033 ASP 270
  • TABLE 200 CANADA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (USD MILLION) 270
  • TABLE 201 CANADA CHIN IMPLANT IN FAT REDUCTION MARKET, BY SMOOTH IMPLANTS, 2019-2033 (NUMBER OF PROCEDURES) 271

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA FAT REDUCTION MARKET: SEGMENTATION 56
  • FIGURE 2 NORTH AMERICA FAT REDUCTION MARKET: DATA TRIANGULATION 59
  • FIGURE 3 NORTH AMERICA FAT REDUCTION MARKET: DROC ANALYSIS 60
  • FIGURE 4 NORTH AMERICA FAT REDUCTION MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS 61
  • FIGURE 5 NORTH AMERICA FAT REDUCTION MARKET: COMPANY RESEARCH ANALYSIS 61
  • FIGURE 6 NORTH AMERICA FAT REDUCTION MARKET: INTERVIEW DEMOGRAPHICS 62
  • FIGURE 7 NORTH AMERICA FAT REDUCTION MARKET: MULTIVARIATE MODELLING 63
  • FIGURE 8 NORTH AMERICA FAT REDUCTION MARKET: DBMR MARKET POSITION GRID 64
  • FIGURE 9 NORTH AMERICA FAT REDUCTION MARKET: VENDOR SHARE ANALYSIS 65
  • FIGURE 10 NORTH AMERICA FAT REDUCTION MARKET: MARKET APPLICATION COVERAGE GRID 66
  • FIGURE 11 NORTH AMERICA FAT REDUCTION MARKET: SEGMENTATION 70
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA FAT REDUCTION MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2033 71
  • FIGURE 13 INCREASING DEMAND FOR NON-INVASIVE AND MINIMALLY INVASIVE AESTHETIC PROCEDURES IS EXPECTED TO DRIVE THE NORTH AMERICA FAT REDUCTION MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2033 72
  • FIGURE 14 THE SURGICAL FAT REDUCTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA FAT REDUCTION MARKET IN 2023 & 2033 72
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR THE FAT REDUCTION MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2033 73
  • FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA FAT REDUCTION MARKET 132
  • FIGURE 17 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE, 2022 147
  • FIGURE 18 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE, 2023-2033 (USD MILLION) 148
  • FIGURE 19 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE, CAGR (2023-2033) 148
  • FIGURE 20 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE, LIFELINE CURVE 149
  • FIGURE 21 NORTH AMERICA FAT REDUCTION MARKET: BY APPLICATION, 2022 177
  • FIGURE 22 NORTH AMERICA FAT REDUCTION MARKET: BY APPLICATION, 2023-2033 (USD MILLION) 178
  • FIGURE 23 NORTH AMERICA FAT REDUCTION MARKET: BY APPLICATION, CAGR (2023-2033) 178
  • FIGURE 24 NORTH AMERICA FAT REDUCTION MARKET: BY APPLICATION, LIFELINE CURVE 179
  • FIGURE 25 NORTH AMERICA FAT REDUCTION MARKET: BY GENDER, 2022 188
  • FIGURE 26 NORTH AMERICA FAT REDUCTION MARKET: BY GENDER, 2023-2033 (USD MILLION) 189
  • FIGURE 27 NORTH AMERICA FAT REDUCTION MARKET: BY GENDER, CAGR (2023-2033) 189
  • FIGURE 28 NORTH AMERICA FAT REDUCTION MARKET: BY GENDER, LIFELINE CURVE 190
  • FIGURE 29 NORTH AMERICA FAT REDUCTION MARKET: BY AGE GROUP, 2022 194
  • FIGURE 30 NORTH AMERICA FAT REDUCTION MARKET: BY AGE GROUP, 2023-2033 (USD MILLION) 195
  • FIGURE 31 NORTH AMERICA FAT REDUCTION MARKET: BY AGE GROUP, CAGR (2023-2033) 195
  • FIGURE 32 NORTH AMERICA FAT REDUCTION MARKET: BY AGE GROUP, LIFELINE CURVE 196
  • FIGURE 33 NORTH AMERICA FAT REDUCTION MARKET: BY END USER, 2022 202
  • FIGURE 34 NORTH AMERICA FAT REDUCTION MARKET: BY END USER, 2023-2033 (USD MILLION) 203
  • FIGURE 35 NORTH AMERICA FAT REDUCTION MARKET: BY END USER, CAGR (2023-2033) 203
  • FIGURE 36 NORTH AMERICA FAT REDUCTION MARKET: BY END USER, LIFELINE CURVE 204
  • FIGURE 37 NORTH AMERICA FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 213
  • FIGURE 38 NORTH AMERICA FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2023-2033 (USD MILLION) 214
  • FIGURE 39 NORTH AMERICA FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2033) 214
  • FIGURE 40 NORTH AMERICA FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 215
  • FIGURE 41 NORTH AMERICA FAT REDUCTION MARKET: SNAPSHOT (2022) 222
  • FIGURE 42 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022) 223
  • FIGURE 43 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 223
  • FIGURE 44 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 224
  • FIGURE 45 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 224
  • FIGURE 46 NORTH AMERICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 417
  • FIGURE 47 THE U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 418
  • FIGURE 48 ABBVIE INC.IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 419
  • FIGURE 49 CYNOSURE IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 420
  • FIGURE 50 ALMA LASERS IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 421
  • FIGURE 51 CANDELA CORPORATION IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 422
  • FIGURE 52 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 423
  • FIGURE 53 THE CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 424
  • FIGURE 54 ABBVIE INC.IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 425
  • FIGURE 55 CYNOSURE IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 426
  • FIGURE 56 CANDELA CORPORATION IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 427
  • FIGURE 57 ALMA LASERS IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 428
  • FIGURE 58 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 429
  • FIGURE 59 THE MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 430
  • FIGURE 60 ABBVIE INC.IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 431
  • FIGURE 61 ALMA LASERS IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 432
  • FIGURE 62 CANDELA CORPORATION IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 433
  • FIGURE 63 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 434
  • FIGURE 64 THE COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 435
  • FIGURE 65 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 436
  • FIGURE 66 CANDELA CORPORATION IN COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 437
  • FIGURE 67 DEXLEVO AESTHETICS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 438
  • FIGURE 68 THE DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 439
  • FIGURE 69 ABBVIE INC IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 440
  • FIGURE 70 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 441
  • FIGURE 71 THE GUATEMALA S FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 442
  • FIGURE 72 ALMA LASERS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 443
  • FIGURE 73 CANDELA CORPORATION IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 444
  • FIGURE 74 THE HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 445
  • FIGURE 75 ALMA LASERS IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 446
  • FIGURE 76 CANDELA CORPORATION IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 447

 

  • FIGURE 77 THE PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 448
  • FIGURE 78 ALMA LASERS IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 449
  • FIGURE 79 CANDELA CORPORATION IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 450
  • FIGURE 80 THE EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 451
  • FIGURE 81 ALMA LASERS IN EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 452
  • FIGURE 82 THE NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 453
  • FIGURE 83 ALMA LASERS IN NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 454
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!